Developmentally-regulated expression of murine K-ras isoforms
Abstract
The products (p21) of the three mammalian H-, N- and K-ras genes play important roles in intracellular signal transduction, linking membrane receptor kinases to the nuclear pathway through raf and mitogen activated protein kinase. They are involved in the regulation of proliferation and differentiation, and activating mutations of these genes are commonly associated with human cancers. Two p21 proteins are encoded by the K-ras gene (p21K-rasA and p21K-rasB) due to alternative splicing of the last exon. While the four p21ras proteins are highly homologous, their sequences diverge significantly at the C-termini, to which distinct biochemical and perhaps even functional differences may be ascribed. However, H-, N- and K-rasB appear to be ubiquitously expressed, with little evidence of tissue-specific or developmental regulation. In contrast, we now demonstrate that the expression of K-rasA is strikingly different. K-rasA is induced during differentiation of pluripotent embryonal stem cells in vitro. Its expression during early embryogenesis is limited temporally and spatially in a tissue-specific distribution which is largely maintained as an adult. This suggests a distinct biological role for p21K-rasA.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Activated KRAS is associated with tumorigenesis, aggressive disease, and poor prognosis.
“The activated state of KRAS accumulating in vivo results in the activation of downstream signaling pathways and is associated with tumorigenesis, aggressive disease, and poor prognosis [14, 15].”
From Targeting KRAS mutant cancers: from druggable therapy to drug resistance (2022) · cites this paper as [14]
The activated state of KRAS accumulating in vivo results in activation of downstream signaling pathways.
“The activated state of KRAS accumulating in vivo results in the activation of downstream signaling pathways and is associated with tumorigenesis, aggressive disease, and poor prognosis [14, 15].”
From Targeting KRAS mutant cancers: from druggable therapy to drug resistance (2022) · cites this paper as [14]
Cites
Silver, L. M., Martin, G. R., & Strickland, S. (1983) · Medical Entomology and Zoology · Cited by 248 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
RAS-targeted therapies: is the undruggable drugged?
Moore, A. R., Rosenberg, S. C., McCormick, F., & Malek, S. (2020) · Nature Reviews Drug Discovery · doi:10.1038/s41573-020-0068-6 · Cited by 1,103 · see citing works
JAK/STAT, Raf/MEK/ERK, PI3K/Akt and BCR-ABL in cell cycle progression and leukemogenesis
Steelman, L. S., Pohnert, S. C., Shelton, J. G., Franklin, R. A., Bertrand, F. E., & McCubrey, J. A. (2004) · Leukemia · doi:10.1038/sj.leu.2403241 · Cited by 681 · see citing works
Role of oncogenic KRAS in the prognosis, diagnosis and treatment of colorectal cancer
Zhu, G., Pei, L., Xia, H., Tang, Q., & Bi, F. (2021) · Molecular Cancer · doi:10.1186/s12943-021-01441-4 · Cited by 482 · see citing works
Reuter, C. W., Morgan, M. A., & Bergmann, L. (2000) · Blood · doi:10.1182/blood.v96.5.1655 · Cited by 300 · see citing works
Esteban, L. M., Vicario‐Abejón, C., Fernández‐Salguero, P. M., Fernández‐Medarde, A., Swaminathan, N., Yienger, K., Lopez, E., Malumbres, M., McKay, R. D. G., Ward, J. M., et al. (2001) · Molecular and Cellular Biology · doi:10.1128/mcb.21.5.1444-1452.2001 · Cited by 298 · see citing works
Voice, J. K., Klemke, R. L., Le, A., & Jackson, J. H. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.24.17164 · Cited by 288 · see citing works
Functional Specificity of Ras Isoforms: So Similar but So Different
Castellano, E., & Santos, E. (2011) · Genes & Cancer · doi:10.1177/1947601911408081 · Cited by 273 · see citing works
RAS pathways to cell cycle control and cell transformation
Pellicer, À. (1998) · Frontiers in bioscience · doi:10.2741/a331 · Cited by 248 · see citing works
Targeting KRAS mutant cancers: from druggable therapy to drug resistance
Zhu, C., Guan, X., Zhang, X., Luan, X., Song, Z., Cheng, X., Zhang, W., & Qin, J.-J. (2022) · Molecular Cancer · doi:10.1186/s12943-022-01629-2 · Cited by 231 · see citing works
K-Ras4A splice variant is widely expressed in cancer and uses a hybrid membrane-targeting motif
Tsai, F. D., Lopes, M. S., Zhou, M., Court, H., Ponce, O., Fiordalisi, J. J., Gierut, J. J., Cox, A. D., Haigis, K. M., & Philips, M. R. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1412811112 · Cited by 226 · see citing works
Ras and relatives—job sharing and networking keep an old family together
Ehrhardt, A., Ehrhardt, G. R. A., Guo, X., & Schrader, J. W. (2002) · Experimental Hematology · doi:10.1016/s0301-472x(02)00904-9 · Cited by 184 · see citing works
Ellis, C. A., & Clark, G. (2000) · Cellular Signalling · doi:10.1016/s0898-6568(00)00084-x · Cited by 145 · see citing works
Ras family genes: An interesting link between cell cycle and cancer
Macaluso, M., Russo, G. L., Cinti, C., Bazan, V., Gebbia, V., & Russo, A. D. (2002) · Journal of Cellular Physiology · doi:10.1002/jcp.10109 · Cited by 145 · see citing works
Ras Proteins: Recent Advances and New Functions
Rebollo, A., & Martínez‐A, C. (1999) · Blood · doi:10.1182/blood.v94.9.2971 · Cited by 140 · see citing works
Cancer initiation and progression: Involvement of stem cells and the microenvironment
Tysnes, B. B., & BJERKVIG, R. (2007) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2007.01.001 · Cited by 133 · see citing works
The genetics and biology of KRAS in lung cancer
Westcott, P. M. K., & To, M. D. (2013) · Chinese Journal of Cancer · doi:10.5732/cjc.012.10098 · Cited by 116 · see citing works
Kras regulatory elements and exon 4A determine mutation specificity in lung cancer
To, M. D., Wong, C. E., Karnezis, A. N., Rosario, R. D., Lauro, R. D., & Balmain, A. (2008) · Nature Genetics · doi:10.1038/ng.211 · Cited by 117 · see citing works
Plowman, S. J., Williamson, D. J., O’Sullivan, M. J., Doig, J., Ritchie, A., Harrison, D. J., Melton, D. W., Arends, M. J., Hooper, M., & Patek, C. E. (2003) · Molecular and Cellular Biology · doi:10.1128/mcb.23.24.9245-9250.2003 · Cited by 104 · see citing works
Self-citationAldosterone-induced mesangial cell proliferation is mediated by EGF receptor transactivation
Huang, S., Zhang, A., Ding, G., & Chen, R. (2009) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.90428.2008 · Cited by 98 · see citing works
Regulation of Na+ Reabsorption by the Aldosterone-induced Small G Protein K-Ras2A
Stockand, J. D., Spier, B. J., Worrell, R. T., Yue, G., Al-Baldawi, N. F., & Eaton, D. C. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.50.35449 · Cited by 82 · see citing works
Development of Synthetic Lethality Anticancer Therapeutics
Fang, B. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm500415t · Cited by 71 · see citing works
Plowman, S. J., Berry, R. L., Bader, S. A., Luo, F., Arends, M. J., Harrison, D. J., Hooper, M. L., & Patek, C. E. (2006) · PubMed · Cited by 70 · see citing works
Self-citationIchise, T., Yoshida, N., & Ichise, H. (2010) · Development · doi:10.1242/dev.043489 · Cited by 62 · see citing works
Quantification of spatiotemporal patterns of Ras isoform expression during development
Newlaczyl, A. U., Coulson, J. M., & Prior, I. A. (2017) · Scientific Reports · doi:10.1038/srep41297 · Cited by 58 · see citing works
Targeting KRAS4A splicing through the RBM39/DCAF15 pathway inhibits cancer stem cells
Chen, W.-C., To, M. D., Westcott, P. M. K., Delrosario, R., Kim, I.-J., Philips, M. R., Tran, Q., Bollam, S., Goodarzi, H., Bayani, N., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-24498-7 · Cited by 52 · see citing works
Chakrabarti, M., Jang, H., & Nussinov, R. (2016) · The Journal of Physical Chemistry B · doi:10.1021/acs.jpcb.5b11110 · Cited by 52 · see citing works
Genetic and Biochemical Alterations in Non-Small Cell Lung Cancer
Johnson, J. L., Pillai, S., & Chellappan, S. (2012) · Biochemistry Research International · doi:10.1155/2012/940405 · Cited by 50 · see citing works
Singh, A. K., Sowjanya, A. P., & Ramakrishna, G. (2005) · The FASEB Journal · doi:10.1096/fj.04-2584hyp · Cited by 47 · see citing works
Hendron, E., & Stockand, J. D. (2002) · Molecular Biology of the Cell · doi:10.1091/mbc.e02-05-0260 · Cited by 49 · see citing works
Floyd, H. S., Farnsworth, C. L., Kock, N. D., Mizesko, M. C., Little, J. L., Dance-Barnes, S. T., Everitt, J. I., Tichelaar, J. W., Whitsett, J. A., & Miller, M. S. (2005) · Carcinogenesis · doi:10.1093/carcin/bgi190 · Cited by 46 · see citing works
The role of KRAS splice variants in cancer biology
Nuevo‐Tapioles, C., & Philips, M. R. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2022.1033348 · Cited by 46 · see citing works
Plowman, S. J., Arends, M. J., Brownstein, D. G., Luo, F., Devenney, P. S., ROSE, L., RITCHIE, A., BERRY, R., Harrison, D. J., & Hooper, M. M. (2005) · Experimental Cell Research · doi:10.1016/j.yexcr.2005.10.004 · Cited by 42 · see citing works
Self-citationKhalaf, W. F., Yang, F., Shi, C., White, H. A., Bessler, W., Ingram, D. A., & Clapp, D. W. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.178.4.2527 · Cited by 40 · see citing works
RAS interaction with Sin1 is dispensable for mTORC2 assembly and activity
Castel, P., Dharmaiah, S., Sale, M. J., Messing, S. A. J., Rizzuto, G. A., Cuevas-Navarro, A., Cheng, A. S., Trnka, M. J., Urisman, A., Esposito, D., et al. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2103261118 · Cited by 38 · see citing works
Targeting RAS mutants in malignancies: successes, failures, and reasons for hope
Yang, H. S., Zhou, X., Fu, D., Le, C., Wang, J., Zhou, Q., Liu, X., Yuan, Y., Ding, K., & Xiao, Q. (2022) · 癌症:英文版 · doi:10.1002/cac2.12377 · Cited by 35 · see citing works
Liu, B., Yang, P., Ye, Y., Zhou, Y., Li, L., Tashiro, S., Onodera, S., & Ikejima, T. (2011) · Free Radical Research · doi:10.3109/10715762.2011.580343 · Cited by 36 · see citing works
Ross, P. J., George, M. L., Cunningham, D., Di-Stefano, F., Andreyev, J. N., Workman, P., & Clarke, P. A. (2001) · PubMed · Cited by 36 · see citing works
Fang, B. (2015) · Acta Biochimica et Biophysica Sinica · doi:10.1093/abbs/gmv090 · Cited by 35 · see citing works
Zhang, X., Cao, J., Miller, S. P., Jing, H., & Lin, H. (2017) · ACS Central Science · doi:10.1021/acscentsci.7b00440 · Cited by 34 · see citing works
Ras and Ras mutations in cancer
Rajasekharan, S., & Raman, T. (2013) · Open Life Sciences · doi:10.2478/s11535-013-0158-5 · Cited by 33 · see citing works
Oncogenic KRAS engages an RSK1/NF1 pathway to inhibit wild-type RAS signaling in pancreatic cancer
Cheng, D. K., Oni, T. E., Thalappillil, J. S., Park, Y., Ting, H.-C., Alagesan, B., Prasad, N. V., Addison, K., Rivera, K. D., Pappin, D. J., et al. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2016904118 · Cited by 30 · see citing works
K-Ras4B/calmodulin/PI3Kα: A promising new adenocarcinoma-specific drug target?
Nussinov, R., Muratcioğlu, S., Tsai, C., Jang, H., Gürsoy, A., & Keskin, Ö. (2015) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2016.1135131 · Cited by 30 · see citing works
Roles of palmitoylation and the KIKK membrane-targeting motif in leukemogenesis by oncogenic KRAS4A
Zhao, H., Liu, P., Zhang, R., Wu, M. H., Li, D., Zhao, X., Zhang, C., Jiao, B., Chen, B., Chen, Z., et al. (2015) · Journal of Hematology & Oncology · doi:10.1186/s13045-015-0226-1 · Cited by 30 · see citing works
Mutationally activated K-ras 4A and 4B both mediate lung carcinogenesis
Patek, C. E., Arends, M. J., Wallace, W. A., Luo, F., Hagan, S., Brownstein, D. G., Rose, L., Devenney, P. S., Walker, M., Plowman, S. J., et al. (2007) · Experimental Cell Research · doi:10.1016/j.yexcr.2007.11.004 · Cited by 28 · see citing works
Self-citationThe renewed battle against RAS-mutant cancers
Zhang, F., & Cheong, J. K. (2016) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-016-2155-8 · Cited by 29 · see citing works
Liu, Z., Kullman, S. W., Bencic, D. C., TORTEN, M., & Hinton, D. E. (2003) · Mutation Research/Genetic Toxicology and Environmental Mutagenesis · doi:10.1016/s1383-5718(03)00133-5 · Cited by 28 · see citing works
The role of alternative pre-mRNA splicing in cancer progression
Choi, S., Cho, N., Kim, E.-M., & Kim, K. K. (2023) · Cancer Cell International · doi:10.1186/s12935-023-03094-3 · Cited by 27 · see citing works
Mouse models of K-ras-initiated carcinogenesis
Janssen, K., Abala, M., Marjou, F. E., Louvard, D., & Robine, S. (2005) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2005.07.004 · Cited by 26 · see citing works
Mammalian K-ras2 Is a Corticosteroid-Induced Gene in Vivo
Brennan, F. E., & Fuller, P. J. (2006) · Endocrinology · doi:10.1210/en.2005-1481 · Cited by 24 · see citing works
Effect of ginger extracts on colorectal cancer HCT-116 cell line in the expression of MMP-2 and KRAS
Malmir, S., Ebrahimi, A., & Mahjoubi, F. (2020) · Gene Reports · doi:10.1016/j.genrep.2020.100824 · Cited by 23 · see citing works
Abate‐Pella, D., Zeliadt, N. A., Ochocki, J. D., Warmka, J. K., Dore, T. M., Blank, D. A., Wattenberg, E. V., & Distefano, M. D. (2012) · ChemBioChem · doi:10.1002/cbic.201200063 · Cited by 23 · see citing works
Methionine 170 is an Environmentally Sensitive Membrane Anchor in the Disordered HVR of K-Ras4B
Neale, C., & Garcı́a, A. E. (2018) · The Journal of Physical Chemistry B · doi:10.1021/acs.jpcb.8b07919 · Cited by 20 · see citing works
Decreased GTPase activity of K- ras mutants deriving from human functional adrenocortical tumours
Lin, S.-R., Hsu, C.-H., Tsai, J. H., Wang, J.-Y., Hsieh, T.-J., & Wu, C.-H. (2000) · British Journal of Cancer · doi:10.1054/bjoc.1999.1039 · Cited by 21 · see citing works
P19 H-Ras Induces G1/S Phase Delay Maintaining Cells in a Reversible Quiescence State
Camats, M., Kokolo, M., Heesom, K. J., Ladomery, M., & Bach‐Elias, M. (2009) · PLoS ONE · doi:10.1371/journal.pone.0008513 · Cited by 20 · see citing works
Progress of Immune Checkpoint Inhibitors Therapy for pMMR/MSS Metastatic Colorectal Cancer
Qu, F., Wu, S., & Yu, W. (2024) · OncoTargets and Therapy · doi:10.2147/ott.s500281 · Cited by 20 · see citing works
Circular RNAs in the KRAS pathway: Emerging players in cancer progression
Hussain, M. S., Moglad, E. H. O., Afzal, M., Bansal, P., Kaur, H., Deorari, M., Ali, H., Shahwan, M. J., Almalki, W. H., Kazmi, I. A., et al. (2024) · Pathology - Research and Practice · doi:10.1016/j.prp.2024.155259 · Cited by 20 · see citing works
Splice variants of RAS—translational significance
Rásó, E. (2020) · Cancer and Metastasis Reviews · doi:10.1007/s10555-020-09920-8 · Cited by 19 · see citing works
Connecting the dots: LncRNAs in the KRAS pathway and cancer
Maqbool, M., Hussain, M. S., Bisht, A. S., Kumari, A., Kamran, A., Sultana, A., Kumar, R., Khan, Y., & Gupta, G. (2024) · Pathology - Research and Practice · doi:10.1016/j.prp.2024.155570 · Cited by 18 · see citing works
Oualid, F. E., Bruining, L., Leroy, I. M., Cohen, L., BOOM, J. H. V., van der MAREL, G. A., Overkleeft, H. S., & Overhand, M. (2002) · Helvetica Chimica Acta · doi:10.1002/1522-2675(200210)85:10 · Cited by 18 · see citing works
Mouse Pulmonary Adenoma Susceptibility 1 Locus Is an Expression QTL Modulating Kras-4A
Dassano, A., Colombo, F., Trincucci, G., Frullanti, E., Galvan, A., Pettinicchio, A., Cecco, L. D., Borrego, A., Ibañez, O. M., Dragani, T. A., et al. (2014) · PLoS Genetics · doi:10.1371/journal.pgen.1004307 · Cited by 17 · see citing works
Aran, V., Domingues, P. M., de Macedo, F. C., de Sousa, C. A. M., Montella, T. C., Accioly, M. T. D. S., & Ferreira, C. G. (2017) · Lung Cancer · doi:10.1016/j.lungcan.2017.12.005 · Cited by 15 · see citing works
Oualid, F. E., Burm, B. E. A., Leroy, I. M., Cohen, L., BOOM, J. H. V., van den Elst, H., Overkleeft, H. S., van der MAREL, G. A., & Overhand, M. (2004) · Journal of Medicinal Chemistry · doi:10.1021/jm049927q · Cited by 15 · see citing works
Farnesylthiosalicylic acid induces caspase activation and apoptosis in glioblastoma cells
Amos, S., Redpath, G. T., Polar, G. A., McPheson, R., Schiff, D., & Hussaini, I. M. (2005) · Cell Death and Differentiation · doi:10.1038/sj.cdd.4401783 · Cited by 14 · see citing works
Comparison of liver oncogenic potential among human RAS isoforms
Chung, S. I., Moon, H., Ju, H.-L., Kim, D. Y., Cho, K. J., Ribback, S., Dombrowski, F., Calvisi, D. F., & Ro, S. W. (2016) · Oncotarget · doi:10.18632/oncotarget.6931 · Cited by 13 · see citing works
Henkels, K. M., Rehl, K. M., & Cho, K. (2021) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2021.673096 · Cited by 12 · see citing works
Regulation of KRAS4A/B splicing in cancer stem cells by the RBM39 splicing complexPreprint
Chen, W.-C., To, M. D., Westcott, P. M. K., Delrosario, R., Kim, I.-J., Philips, M. R., Tran, Q., Bayani, N., & Balmain, A. (2019) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/646125 · Cited by 11 · see citing works
Patek, C. E., Arends, M. J., Rose, L., Luo, F., Walker, M., Devenney, P. S., Berry, R. L., Lawrence, N. J., Ridgway, R. A., Sansom, O. J., et al. (2008) · BMC Gastroenterology · doi:10.1186/1471-230x-8-24 · Cited by 10 · see citing works
Self-citationBratei, A. A., & Staden, R. S. (2023) · Medinformatics · doi:10.47852/bonviewmedin32021546 · Cited by 9 · see citing works
Differential functions of the KRAS splice variants
Rossi, J. A. K., Nuevo‐Tapioles, C., & Philips, M. R. (2023) · Biochemical Society Transactions · doi:10.1042/bst20221347 · Cited by 8 · see citing works
Yang, D., Lai, X., Xu, F., Li, Y., Jiang, W., & Ma, D. (2019) · Europe PMC (PubMed Central) · Cited by 8 · see citing works
K-RAS4A: Lead or Supporting Role in Cancer Biology?
Aran, V. (2021) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2021.729830 · Cited by 8 · see citing works
Ebrahimie, E., Rahimirad, S., Tahsili, M. R., & Dehcheshmeh, M. M. (2021) · World Journal of Stem Cells · doi:10.4252/wjsc.v13.i10.1394 · Cited by 8 · see citing works
KRASG12C Inhibitors in Non-Small Cell Lung Cancer: A Review
Tang, M., Wu, Y., Bai, X., & Lü, Y. (2024) · OncoTargets and Therapy · doi:10.2147/ott.s473368 · Cited by 7 · see citing works
Activation of small GTPases of the Ras and Rho family by growth factors active on mast cells
Schrader, J. W., Schallhorn, A., Grill, B. J., & Guo, X. (2002) · Molecular Immunology · doi:10.1016/s0161-5890(02)00060-3 · Cited by 6 · see citing works
Oualid, F. E., Baktawar, J., Leroy, I. M., van den Elst, H., Cohen, L., van der MAREL, G. A., Overkleeft, H. S., & Overhand, M. (2005) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2004.12.035 · Cited by 6 · see citing works
Different Ras isoforms regulate synaptic plasticity in opposite directions
López-Merino, E., Fernández‐Rodrigo, A., Jiang, J. G., Gutiérrez-Eisman, S., de Sevilla, D. F., Fernández‐Medarde, A., Santos, E., Guerra, C. E., Barbacid, M., Esteban, J. A., et al. (2025) · The EMBO Journal · doi:10.1038/s44318-025-00390-8 · Cited by 5 · see citing works
RAS: Circuitry and therapeutic targeting
Singh, G., Thakur, N., & Kumar, U. (2022) · Cellular Signalling · doi:10.1016/j.cellsig.2022.110505 · Cited by 5 · see citing works
Oncogenic KRAS engages an RSK1/NF1 complex in pancreatic cancerPreprint
Cheng, D. K., Oni, T. E., Park, Y., Thalappillil, J. S., Ting, H.-C., Alagesan, B., Prasad, N. V., Rivera, K. D., Pappin, D., Aelst, L. V., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.09.14.295394 · Cited by 3 · see citing works
Biochemical Pathways in Cancer
Breuer, E.-K. Y., Murph, M. M., & Craven, R. J. (2012) · Biochemistry Research International · doi:10.1155/2012/268504 · Cited by 1 · see citing works
Ras Signaling Pathways and Farnesyltransferase Inhibitors
Mukherjee, J., & Guha, A. (2006) · Elsevier eBooks · doi:10.1016/b978-012088410-0/50050-0 · Cited by 1 · see citing works
The Biology of K-Ras Signaling Pathways in Pancreatic Cancer
Court, H., Philips, M. R., & Bar‐Sagi, D. (2013) · Springer eBooks · doi:10.1007/978-1-4614-6549-2_5
Alteracions de la VIA RAS-RAF en càncer gastrointestinal amb defectes de reparació genòmica
Domingo, E. (2007) · LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas)
H-Ras Pre-mRNA Contains A Regulatory Non-coding RNA
Kokolo, M., & Bach‐Elias, M. (2020) · OBM Genetics · doi:10.21926/obm.genet.2004118
BindingDB Entry 50045098: Development of synthetic lethality anticancer therapeutics.
BindingDB (2016) · UC San Diego · doi:10.7270/q2vd714c
- Authors
- Pells, S., Divjak, M., Romanowski, P., Impey, H., Hawkins, N. J., Clarke, A. R., Hooper, M. L., & Williamson, D. J.
- Affiliations
- University of Edinburgh (GB)
- St Vincent's Hospital Sydney (AU)
- UNSW Sydney (AU)
- Venue
- Oncogene
- Published
- 1997-10-09
- Volume
- 15
- Issue
- 15
- Pages
- 1781-1786
- ISSN
- 0950-9232 (ISSN-L)
- 1476-5594
- OpenAlex
- W2314235576
- Cited by
- 83
- References
- 1
- Citations by year
- 2025: 1 · 2024: 4 · 2023: 3 · 2022: 4 · 2021: 7 · 2020: 5 · 2019: 2 · 2018: 1 · 2017: 3 · 2016: 3 · 2015: 4 · 2014: 2 · 2013: 2 · 2012: 4
- FWCI
- 0.83
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Oncogene (publishedVersion)
- PubMed (publishedVersion)
- Funders
- University of Sussex
- University of Edinburgh
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Developmental Biology and Gene Regulation
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Tyrosine Phosphatases
- Keywords
- KRAS, alternative splicing, developmental regulation, embryonic development, tissue-specific gene expression, p21ras, signal transduction, Raf, mitogen-activated protein kinase, cell proliferation and differentiation
- MeSH terms
- Animals, Cell Differentiation, Humans, Mice, Inbred BALB C, Genes, ras, RNA, Messenger, Alternative Splicing, Gene Expression Regulation, Developmental, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review